Italian survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: A lesson for the second wave.
Journal Information
Full Title: Crit Rev Oncol Hematol
Abbreviation: Crit Rev Oncol Hematol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Declaration of Competing Interest Novello S declared speaker bureau/advisor’s fee from Eli Lilly, MSD, Roche, BMS, Takeda, Pfizer, Astra Zeneca and Boehringer Ingelheim. Passiglia F declared consultant’s fee from MSD, Boehringer Ingelheim and AstraZeneca. Bironzo P declared consultant’s fee from MSD, BMS, AstraZeneca, BeiGene and Roche. Capelletto E declared consultant’s fee from MSD, AstraZeneca, Boehringer Ingelheim. Other co-authors have no COI to declare."
"Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025